Xavier P.
- Country
- France
- Department
- Centre Eugène Marquis (CEM)
Research Overview
Data & Insights
Has run more than one trial at 0 of 6 partner sites.
Specializations
Advanced Solid Tumors & Immunotherapy
Focused on the integration of immune‑modulating agents for a broad spectrum of high‑risk solid malignancies.
- immune checkpoint blockade
- metastatic solid tumors
- high mutational burden cancers
- MSI‑High tumors
- combination immunotherapy regimens
Efforts target durable responses across diverse histologies by leveraging synergistic immune pathways.
Hepatobiliary Oncology
Dedicated to therapeutic strategies for liver and bile‑duct malignancies, emphasizing targeted and systemic options.
- hepatocellular carcinoma
- biliary tract carcinoma
- cholangiocarcinoma
- radio‑embolization
- FGFR‑targeted therapy
Research aims to improve survival in patients with unresectable or advanced disease.
Breast Cancer Therapeutics
Explores endocrine, HER2‑directed, and novel molecular approaches for hormone‑responsive and HER2‑altered breast cancers.
- HR‑positive/HER2‑negative disease
- HER2‑positive metastatic breast cancer
- triple‑negative breast cancer
- CDK4/6 inhibitor resistance
- PIK3CA‑mutated tumors
Initiatives include de‑escalation strategies and precision‑medicine driven treatment selection.
Prostate Cancer & Hormone Pathways
Concentrates on advanced prostate malignancies, addressing castration‑resistant disease and hormone‑sensitive progression.
- metastatic castration‑resistant prostate cancer
- hormone‑naïve prostate cancer
- androgen receptor targeting
- PSMA‑directed imaging
- oligometastatic prostate disease
Studies aim to extend disease control through novel hormonal and radiopharmaceutical interventions.
Rare Tumors & Molecularly Targeted Therapies
Addresses uncommon sarcomas, neuroendocrine neoplasms, and genetically defined cancers with precision agents.
- soft‑tissue sarcoma
- neuroendocrine tumors
- FGFR‑fusion driven malignancies
- BRAF‑mutated cancers
- DNA‑repair deficient tumors
The focus is on exploiting actionable genomic alterations to achieve therapeutic benefit in low‑incidence cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.